Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

SalubrisBio Raises $32 Million from China Parent for Novel Biologics

publication date: Mar 7, 2022

SalubrisBio of Maryland received $32 million from its parent, Shenzhen Salubris Pharma, to develop its portfolio of complex novel biologic products. SalubrisBio’s lead asset is an antibody-based NRG-1 fusion protein, the first bi-specific antibody to start trials for a cardiovascular indication. JK07 is currently in a Phase I test among heart failure patients with reduced ejection fraction. The investment will support the ongoing Phase Ib trial plus two additional Phase Ib trials in 2022, while the company expands its R&D pipeline. SalubrisBio develops products for unmet needs in cardiovascular diseases, cancer and neurodegenerative diseases. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital